Business Overview: Filana Therapeutics, Inc. (NASDAQ: FLNA)

---

Executive Summary

Filana Therapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, with no approved products and no product revenue. The company was originally incorporated in Delaware in 1998 as Pain Therapeutics, Inc., renamed Cassava Sciences, Inc. in 2019 after pivoting toward Alzheimer's disease, and renamed again to Filana Therapeutics, Inc. on March 10, 2026, after its lead Alzheimer's program failed and the company pivoted to a new indication for the same drug.

The company's history is unusually eventful for a small biotech: as Cassava Sciences, it became the center of a years-long controversy over the integrity of research supporting its Alzheimer's drug simufilam, including an SEC enforcement action, a $40 million settlement penalty, a DOJ investigation into a collaborating academic researcher, and ultimately the failure of two Phase 3 trials in 2024–2025 that ended the Alzheimer's program entirely. Filana now matters as a case study in binary, single-asset clinical-stage biotech risk: it is re-purposing its one drug candidate, simufilam, for a narrow, rare-disease indication — tuberous sclerosis complex (TSC)-related epilepsy — while working through a regulatory setback (an FDA clinical hold) and the financial aftermath of its legal history.

---

1. Core Business Model & How They Work

Filana has no commercial products and generates no product revenue. Its business model is that of a lean, outsourced clinical-stage drug developer: it licenses or owns intellectual property around a drug candidate, outsources most preclinical/clinical work and manufacturing to contract organizations, and funds operations through its existing cash balance and (potentially) future capital raises.

[ Licensed/Owned IP (Filamin A mechanism; exclusive Yale license for TSC-epilepsy) ]
          ➡️ [ Outsourced Preclinical Studies ]
          ➡️ [ IND Filing with FDA ]
          ➡️ [ Clinical Trials (currently on FDA clinical hold) ]
          ➡️ [ If Cleared: Proof-of-Concept Trial ➡️ Pivotal Trials ➡️ Regulatory Approval ]
          ➡️ [ If Approved: Commercialization in a Narrow Rare-Disease Market ]

Key Operational Drivers

1. Single-Asset Dependence: The company's entire pipeline currently rests on simufilam, a small-molecule oral drug targeting filamin A, a brain scaffolding protein.
2. Pivot to Rare Disease: After simufilam's Alzheimer's program (two failed Phase 3 trials) was phased out in Q2 2025, the company re-targeted the same molecule at TSC-related epilepsy, a rare, genetically defined seizure disorder.
3. Licensed IP: Filana holds an exclusive worldwide license (with sublicensing rights) from Yale for IP covering simufilam in TSC-related epilepsy, paying up to $4.5 million in milestones plus tiered royalties and possible priority review voucher payments.
4. Lean Cost Structure: The company cut headcount by 33% (10 employees) in January 2025 and ended 2025 with only 17 full-time and 3 part-time employees, reflecting a sharply reduced operating footprint after the Alzheimer's program's failure.
5. Legal/Regulatory Overhang: A large share of recent cash outflow relates to legacy legal costs — the company's FY2025 G&A expense ($68.8M) far exceeded its R&D expense ($26.6M), and it has flagged a possible $31.25 million securities-litigation settlement payment in H1 2026.

---

2. Business Segments

Filana operates as a single-segment clinical-stage biotechnology company; it does not report distinct business segments, as its entire operation is organized around one drug candidate and one active indication (TSC-related epilepsy), with two other programs (the original Alzheimer's use of simufilam, and the SavaDx blood-biomarker program) discontinued in 2025.

---

3. Pipeline Overview

---

4. Competitive Landscape

For TSC-related epilepsy, Filana would compete against two groups of treatments if simufilam is ever approved:

• Traditional anti-seizure medications: vigabatrin (the current standard of care), levetiracetam, valproate, and clobazam — broadly available, genericized drugs with established prescribing patterns.
• Disease-specific treatments: Afinitor Disperz (everolimus, Novartis) — the only FDA-approved drug directly targeting TSC's underlying pathophysiology — and Epidiolex (cannabidiol, Jazz Pharmaceuticals).

                High Disease-Specificity
                        |
      Afinitor Disperz (everolimus) -- targets TSC biology directly
      Epidiolex (cannabidiol) -- TSC-approved, broader epilepsy use
      Simufilam (if approved) -- novel mechanism, unproven in TSC
                        |
                Low Disease-Specificity
      ------------------------------------------
      Narrow/Generic                Broad-Spectrum Anti-Seizure Drugs
      (vigabatrin, levetiracetam, valproate, clobazam)

Beyond direct drug competition, Filana also competes broadly with larger pharmaceutical and biotech companies, academic institutions, and government/research organizations for scientific talent, licensing opportunities, and capital.

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

1. Exclusive Licensed IP: The Yale license gives Filana exclusive worldwide rights to pursue simufilam specifically in TSC-related epilepsy, a real (if narrow) legal barrier to direct replication of its approach.
2. Rare-Disease Focus: TSC-related epilepsy is a small, well-defined patient population; if simufilam is approved, the market may be too small to attract significant new entrants, similar to how everolimus has remained essentially the only disease-specific approved option.
3. Reduced Cost Base: The 2025 headcount reduction and program narrowing have lowered the cash burn needed to keep the company operating while it works through the clinical hold.

Risks

1. FDA Clinical Hold: The FDA placed Filana's proposed TSC-epilepsy trial on full clinical hold on December 15, 2025, after requesting more patient-safety information; the company no longer expects to start the trial before mid-2026, and a hold lasting one year or more could cause the FDA to treat the IND as inactive, potentially ending the program.
2. Single-Asset, Single-Indication Risk: With the Alzheimer's program and SavaDx both discontinued, the entire company now depends on one molecule succeeding in one rare-disease indication with no late-stage efficacy data yet.
3. Legacy Legal and Reputational Overhang: The SEC's 2024 enforcement action (resulting in a $40 million penalty), a DOJ investigation into a collaborating researcher (later dropped in October 2025), and a possible $31.25 million securities-litigation settlement payment in H1 2026 continue to consume cash and credibility built over years as Cassava Sciences.
4. Cash Runway Pressure: The company estimated cash would fall from $95.5 million at year-end 2025 to roughly $47–50 million by June 30, 2026, driven by both operating costs and the potential litigation settlement payment — a meaningful share of its balance sheet.
5. No Approved Products or Revenue: As with most clinical-stage biotechs, the company generates no product revenue and depends entirely on cash reserves and potential future capital raises to fund operations.

---

6. Financial Overview

---

7. Summary Conclusion

Filana Therapeutics is a high-risk, single-asset clinical-stage biotech attempting to reinvent itself after its predecessor, Cassava Sciences, saw its flagship Alzheimer's drug fail Phase 3 trials amid years of research-integrity controversy and an SEC enforcement action. Its remaining moat is thin and narrow: an exclusive licensed claim on simufilam's use in a rare, genetically defined seizure disorder where the only direct competitor (everolimus) has not deterred the company from trying a different mechanism. The single biggest forward risk is binary and immediate — whether the FDA lifts its December 2025 clinical hold in time for the company's remaining cash (already set to be substantially depleted by mid-2026, partly by litigation costs) to fund a meaningful proof-of-concept trial before the capital runs out.